Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

COURTNEY D ACKERMAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1790919744
CMS profile
585146
Location
SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,984.72

127 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,734.73 124
Long term medical supply or device loan $249.99 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
NOVARTIS PHARMACEUTICALS CORPORATION $478.15 12
Janssen Biotech, Inc. $193.47 11
Daiichi Sankyo Inc. $147.37 6
AstraZeneca Pharmaceuticals LP $143.92 8
GlaxoSmithKline, LLC. $104.77 4
GENZYME CORPORATION $103.73 4
Merck Sharp & Dohme LLC $99.35 5
Celgene Corporation $96.05 4
Lilly USA, LLC $88.12 4
E.R. Squibb & Sons, L.L.C. $86.95 4
Mirati Therapeutics, Inc. $78.12 2
PharmaEssentia USA Corporation $77.67 3
Stemline Therapeutics Inc. $76.10 4
Kite Pharma, Inc. $71.01 3
Amgen Inc. $64.83 4
Incyte Corporation $56.90 3
Eisai Inc. $56.43 3
PFIZER INC. $54.61 3
AVEO Pharmaceuticals, Inc. $48.61 2
Exelixis Inc. $48.61 2
Dendreon Pharmaceuticals LLC $48.04 2
Regeneron Healthcare Solutions, Inc. $47.56 2
Seagen Inc. $47.07 2
Rigel Pharmaceuticals, Inc. $44.13 2
Adaptive Biotechnologies Corporation $39.79 1
SOBI, INC $37.67 2
TerSera Therapeutics LLC $36.71 1
ADC Therapeutics America, Inc. $34.73 2
Genmab U.S., Inc. $34.60 1
Astellas Pharma US Inc $33.84 2
G1 Therapeutics, Inc. $33.59 2
TAIHO ONCOLOGY, INC. $33.30 1
Heron Therapeutics, Inc. $31.92 1
Pharmacyclics LLC, An AbbVie Company $29.20 1
Ipsen Biopharmaceuticals, Inc $28.91 1
Sumitomo Pharma America, Inc. $28.30 1
BeiGene USA, Inc. $25.45 1
Takeda Pharmaceuticals U.S.A., Inc. $23.45 1
Telix Pharmaceuticals $23.35 1
Genentech USA, Inc. $19.39 1
Kyowa Kirin, Inc. $18.73 1
ARRAY BIOPHARMA INC $18.27 1
AbbVie Inc. $18.26 1
Acrotech Biopharma Inc. $17.07 1
RECORDATI_RARE_DISEASES_INC. $15.74 1
Myriad Genetic Laboratories, Inc. $13.92 1
Janssen Pharmaceuticals, Inc $13.78 1
Alnylam Pharmaceuticals Inc. $13.18 1

Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

COURTNEY D ACKERMAN

NPI 1790919744 · CMS profile ID 585146

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SILVER SPRING, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790919744?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790919744?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790919744?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
COURTNEY D ACKERMAN, NPI 1790919744, CMS profile ID 585146, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 127 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1790919744?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

127 matching records · $2,984.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 127 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 127.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $21.7908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015012517 CMS
Kite Pharma, Inc. $25.0508/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025266691 CMS
Novartis Pharmaceuticals Corporation $24.1108/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991817809 CMS
PFIZER INC. $23.5008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050697239 CMS
GENZYME CORPORATION $33.6108/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050145793 CMS
Acrotech Biopharma Inc. $17.0708/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052988655 CMS
Janssen Biotech, Inc. $10.2608/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988738489 CMS
Rigel Pharmaceuticals, Inc. $21.7907/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033422025 CMS
ADC Therapeutics America, Inc. $13.8707/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053798177 CMS
Daiichi Sankyo Inc. $29.8407/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006409149 CMS
PharmaEssentia USA Corporation $24.1407/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059316123 CMS
AstraZeneca Pharmaceuticals LP $24.9507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015891039 CMS
Amgen Inc. $19.3507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019872257 CMS
Janssen Biotech, Inc. $25.7307/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988738483 CMS
Ipsen Biopharmaceuticals, Inc $28.9107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045445853 CMS
Kite Pharma, Inc. $23.1407/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025266689 CMS
Merck Sharp & Dohme LLC $18.1607/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048816951 CMS
Novartis Pharmaceuticals Corporation $23.5207/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991817797 CMS
GENZYME CORPORATION $20.2806/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050145745 CMS
Mirati Therapeutics, Inc. $40.8306/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057984741 CMS
Astellas Pharma US Inc $21.1006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034219245 CMS
GlaxoSmithKline, LLC. $24.1506/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001525307 CMS
Janssen Biotech, Inc. $19.9506/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988738499 CMS
AVEO Pharmaceuticals, Inc. $24.3606/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049057553 CMS
Genmab U.S., Inc. $34.6006/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051343557 CMS
RECORDATI_RARE_DISEASES_INC. $15.7406/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060350695 CMS
Mirati Therapeutics, Inc. $37.2906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057984739 CMS
Novartis Pharmaceuticals Corporation $32.2806/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991817793 CMS
GENZYME CORPORATION $25.2006/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050145735 CMS
Amgen Inc. $14.1406/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020557745 CMS
GlaxoSmithKline, LLC. $32.7806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001525319 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3305/31/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435825 CMS
Pharmacyclics LLC, An AbbVie Company $29.2005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280633 CMS
SOBI, INC $19.9805/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038102741 CMS
Dendreon Pharmaceuticals LLC $24.2405/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060277865 CMS
Janssen Biotech, Inc. $23.3705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988738495 CMS
E.R. Squibb & Sons, L.L.C. $14.9605/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015012411 CMS
Myriad Genetic Laboratories, Inc. $13.9205/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059760615 CMS
Regeneron Healthcare Solutions, Inc. $25.5905/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999067657 CMS
Celgene Corporation $19.7005/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015012363 CMS
Eisai Inc. $16.2005/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023306051 CMS
AstraZeneca Pharmaceuticals LP $14.0605/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015746617 CMS
Lilly USA, LLC $22.2205/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031341033 CMS
Stemline Therapeutics Inc. $15.6605/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040023561 CMS
Daiichi Sankyo Inc. $24.3604/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006413243 CMS
G1 Therapeutics, Inc. $19.4404/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059916449 CMS
Novartis Pharmaceuticals Corporation $28.0204/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991817785 CMS
BeiGene USA, Inc. $25.4504/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051195075 CMS
Janssen Biotech, Inc. $24.4604/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988738493 CMS
Astellas Pharma US Inc $12.7404/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034064397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,342.26 116
PY2020 $2,737.59 158
PY2021 $4,287.39 180
PY2022 $3,993.01 184
PY2023 $2,984.72 127
PY2024 $4,292.42 150
PY2025 $3,884.03 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $403,699.59 7
PY2024 Principal investigator $95,481.89 6
PY2023 Principal investigator $416,595.81 7
PY2022 Principal investigator $308,563.37 11
PY2021 Principal investigator $5,100.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,041.97 12/31/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 No dispute reported 06/30/2026 1185555971
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,009.78 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555965
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,244.49 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555973
Principal investigator 1 AstraZeneca Pharmaceuticals LP $358,408.75 01/29/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555969
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,635.40 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185555963
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,566.00 01/15/2025 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555967
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,793.20 01/10/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease No dispute reported 06/30/2026 1185555975